- Home
- SFBS vs IONS Comparison
SFBS vs IONS Comparison
Compare SFBS & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFBS
- IONS
- Stock Information
- Founded
- SFBS 2005
- IONS 1989
- Country
- SFBS United States
- IONS United States
- Employees
- SFBS N/A
- IONS N/A
- Industry
- SFBS Major Banks
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- SFBS Finance
- IONS Health Care
- Exchange
- SFBS Nasdaq
- IONS Nasdaq
- Market Cap
- SFBS 4.1B
- IONS 5.4B
- IPO Year
- SFBS 2014
- IONS 1991
- Fundamental
- Price
- SFBS $74.39
- IONS $33.51
- Analyst Decision
- SFBS Hold
- IONS Buy
- Analyst Count
- SFBS 1
- IONS 18
- Target Price
- SFBS $84.00
- IONS $57.41
- AVG Volume (30 Days)
- SFBS 159.2K
- IONS 1.5M
- Earning Date
- SFBS 07-14-2025
- IONS 04-30-2025
- Dividend Yield
- SFBS 1.80%
- IONS N/A
- EPS Growth
- SFBS 20.55
- IONS N/A
- EPS
- SFBS 4.40
- IONS N/A
- Revenue
- SFBS $477,064,000.00
- IONS $717,253,000.00
- Revenue This Year
- SFBS $25.60
- IONS $7.14
- Revenue Next Year
- SFBS $13.11
- IONS $18.89
- P/E Ratio
- SFBS $16.92
- IONS N/A
- Revenue Growth
- SFBS 17.21
- IONS N/A
- 52 Week Low
- SFBS $58.51
- IONS $23.95
- 52 Week High
- SFBS $101.37
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- SFBS 48.29
- IONS 56.80
- Support Level
- SFBS $73.64
- IONS $32.00
- Resistance Level
- SFBS $75.25
- IONS $33.65
- Average True Range (ATR)
- SFBS 1.42
- IONS 1.08
- MACD
- SFBS -0.11
- IONS -0.10
- Stochastic Oscillator
- SFBS 35.16
- IONS 55.72
About SFBS ServisFirst Bancshares Inc.
Servisfirst Bancshares Inc is a bank holding company whose business is conducted by its wholly owned subsidiary, ServisFirst Bank. Through the bank, it offers various banking services to individual and corporate customers in Birmingham, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. Its various products and service offerings include commercial, consumer, and other loans; accepting deposits; providing electronic banking services, such as online and mobile banking, including remote deposit capture; delivering treasury and cash management services; and providing banking services to other financial institutions. The company operates as a single reportable segment, with a majority of its revenue being derived from the business of banking.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.